Currently, medical textbooks estimate the median survival for advanced breast cancer to be 2 to 3 years.
2
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
3
结论在乳腺癌诊断后生存期至少1年的女性中，使用阿司匹林与乳腺癌远处复发和死亡风险降低密切相关。
Conclusion Among women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death.
点击反馈